Evidence map›Paper›PMID 25749246›Full record

ArticleVaccine2015

Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.

Chris Edens, Naomi C Dybdahl-Sissoko, William C Weldon, M Steven Oberste, Mark R Prausnitz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Engineering of tetanus toxoid-loaded polymeric microneedle patches.Drug delivery and translational research · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Quantum dots against SARS-CoV-2: diagnostic and therapeutic potentials.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chris EdensCoulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Naomi C Dybdahl-SissokoDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
William C WeldonDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
M Steven ObersteDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Mark R PrausnitzCoulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA. Electronic address: prausnitz@gatech.edu.
Centers for Disease Control and Prevention · USGeorgia Institute of Technology · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

The phased replacement of oral polio vaccine (OPV) with inactivated polio vaccine (IPV) is expected to significantly complicate mass vaccination campaigns, which are an important component of the global polio eradication endgame strategy. To simplify mass vaccination with IPV, we developed microneedle patches that are easy to administer, have a small package size, generate no sharps waste and are inexpensive to manufacture. When administered to rhesus macaques, neutralizing antibody titers were equivalent among monkeys vaccinated using microneedle patches and conventional intramuscular injection for IPV types 1 and 2. Serologic response to IPV type 3 vaccination was weaker after microneedle patch vaccination compared to intramuscular injection; however, we suspect the administered type 3 dose was lower due to a flawed pre-production IPV type 3 analytical method. IPV vaccination using microneedle patches was well tolerated by the monkeys. We conclude that IPV vaccination using a microneedle patch is immunogenic in rhesus macaques and may offer a simpler method of IPV vaccination of people to facilitate polio eradication.

Indexed as

Drug Delivery SystemsAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansInjections, IntradermalInjections, IntramuscularMacaca mulattaModels, AnimalPoliovirus Vaccine, InactivatedTreatment OutcomeAntibodies, NeutralizingAntibodies, ViralPoliovirus Vaccine, InactivatedInactivated polio vaccineMicroneedle patchPoliomyelitisRhesus macaqueSharps wasteVaccination

Identifiers

PMID25749246
PMCPMC9044462
OpenAlexW2083707908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.